Eurofins CDMO Alphora Launches AI-Powered Salt and Co-Crystal Screening Software
Event summary
- Eurofins CDMO Alphora launched AI-powered software for high-throughput salt and co-crystal screening on January 26, 2026.
- The software was developed in collaboration with a local university and is now a core component of all solid-state screening programs.
- The machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates.
- The tool aims to streamline solid form selection, reduce trial-and-error experimentation, and lower screening costs.
The big picture
The launch of AI-powered screening software aligns with the broader industry trend of leveraging machine learning to enhance drug development efficiency. Eurofins CDMO Alphora's move underscores the strategic importance of reducing costs and accelerating timelines in the competitive contract development and manufacturing organization (CDMO) market. The collaboration with a local university highlights the growing trend of academic-industry partnerships in driving innovation.
What we're watching
- Adoption Pace
- How quickly clients will integrate the AI-powered software into their drug development processes.
- Cost Efficiency
- Whether the software will significantly reduce development timelines and screening costs as claimed.
- Competitive Edge
- The extent to which this technology differentiates Eurofins CDMO Alphora from competitors in the CDMO space.
Related topics